Interní Med. 2016; 18(2): 91-94 | DOI: 10.36290/int.2016.022
The treatment of type 2 diabetes mellitus is comprehensive where, in addition to recommendations on lifestyle modifications,
pharmacological treatment is initiated the range of which has expanded significantly in recent years. Metformin remains the firstchoice
drug and, according to disease progress, it is possible to choose combinations with other drugs. The present case report
describes the treatment in an obese type 2 diabetic patient who, at the time of diagnosis of his disease, was found to have stage 3
chronic kidney disease that is a contraindication to administering metformin. Following the compensation with insulin treatment,
the patient was commenced on linagliptin once daily that is only minimally eliminated by the kidneys; therefore, there is no need
for its reduction in renal insufficiency. The patient has been treated with linagliptin once daily as monotherapy safely and effectively
for three years while maintaining his weight and having no hypoglycaemias and no further worsening of renal insufficiency.
Published: May 1, 2016 Show citation